BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35768821)

  • 1. Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006-2016.
    Adolph L; Warias A; Stairs J; Collins-McNeil K; Penney L; Kieser K
    BMC Womens Health; 2022 Jun; 22(1):263. PubMed ID: 35768821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.
    Morgan D; Sylvester H; Lucas FL; Miesfeldt S
    Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC.
    Ohsumi S; Nakamura S; Miyata H; Watanabe C; Den H; Arai M
    Jpn J Clin Oncol; 2022 Nov; 52(11):1265-1269. PubMed ID: 35905458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal access to genetic counseling for women with epithelial ovarian cancer in Nova Scotia: Evaluating a new collaborative care model.
    Warias A; Ferguson M; Chamberlain E; Currie L; Snow N; Matheson K; Penney LS; Kieser K
    J Genet Couns; 2021 Oct; 30(5):1491-1499. PubMed ID: 33876505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
    Jacobson M; Bernardini M; Sobel ML; Kim RH; McCuaig J; Allen L
    J Obstet Gynaecol Can; 2018 Nov; 40(11):1497-1510. PubMed ID: 30473125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian.
    Hessock M; Brewer T; Hutson S; Anderson J
    Nurs Womens Health; 2021 Jun; 25(3):187-197. PubMed ID: 33933425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions.
    Wilson BJ; Torrance N; Mollison J; Wordsworth S; Gray JR; Haites NE; Grant A; Campbell MK; Miedyzbrodzka Z; Clarke A; Watson MS; Douglas A
    Health Technol Assess; 2005 Feb; 9(3):iii-iv, 1-126. PubMed ID: 15694064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary breast and ovarian cancer: referral source for genetic assessment and communication regarding assessment with nongenetic clinicians in the community setting.
    Morgan D; Sylvester H; Lucas FL; Miesfeldt S
    Genet Med; 2010 Jan; 12(1):25-31. PubMed ID: 20027114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
    Burling MJ; Gamet K; Eva L; Tan AL
    Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
    Rowley SM; Mascarenhas L; Devereux L; Li N; Amarasinghe KC; Zethoven M; Lee JEA; Lewis A; Morgan JA; Limb S; Young MA; James PA; Trainer AH; Campbell IG
    Genet Med; 2019 Apr; 21(4):913-922. PubMed ID: 30254378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.
    van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP
    Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive testing for hereditary breast and ovarian cancer: a psychological framework for pre-test counselling.
    Decruyenaere M; Evers-Kiebooms G; Denayer L; Welkenhuysen M; Claes E; Legius E; Demyttenaere K
    Eur J Hum Genet; 2000 Feb; 8(2):130-6. PubMed ID: 10757645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.